AR033340A1 - Factor activador de la citoquina altamente purificado y metodos de uso - Google Patents

Factor activador de la citoquina altamente purificado y metodos de uso

Info

Publication number
AR033340A1
AR033340A1 ARP000103782A ARP000103782A AR033340A1 AR 033340 A1 AR033340 A1 AR 033340A1 AR P000103782 A ARP000103782 A AR P000103782A AR P000103782 A ARP000103782 A AR P000103782A AR 033340 A1 AR033340 A1 AR 033340A1
Authority
AR
Argentina
Prior art keywords
activating factor
cytokin
methods
highly purified
caf
Prior art date
Application number
ARP000103782A
Other languages
English (en)
Inventor
Tay N Nguyen
Ruye Xing
Subramanian Iyer
Dauh-Rurng Wu
Original Assignee
Dcv Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dcv Inc filed Critical Dcv Inc
Publication of AR033340A1 publication Critical patent/AR033340A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/85—Reproductive organs or embryos
    • Y10S530/852—Sperm
    • Y10S530/853—Ovary; eggs; embryos

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describe una proteína aislada del factor activador de citoquinas (CAF), una molécula aislada de ácido nucleico que codifica una proteína CAF, un anticuerpo que se une selectivamente a una proteína CAF, una composicion que comprende un factor activador de citoquinas (CAF) y un método para modular el sistema inmunologico usando la composicion. También se describe un método para tratar el cáncer usando dicha composicion
ARP000103782A 1999-07-23 2000-07-21 Factor activador de la citoquina altamente purificado y metodos de uso AR033340A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14531799P 1999-07-23 1999-07-23
US19761900P 2000-04-14 2000-04-14

Publications (1)

Publication Number Publication Date
AR033340A1 true AR033340A1 (es) 2003-12-17

Family

ID=26842849

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103782A AR033340A1 (es) 1999-07-23 2000-07-21 Factor activador de la citoquina altamente purificado y metodos de uso

Country Status (18)

Country Link
US (2) US6420337B1 (es)
EP (1) EP1198475B1 (es)
JP (1) JP4763193B2 (es)
CN (1) CN1376163A (es)
AR (1) AR033340A1 (es)
AT (1) ATE290017T1 (es)
AU (1) AU778239B2 (es)
BR (1) BR0013043A (es)
CA (1) CA2379251A1 (es)
CO (1) CO5290297A1 (es)
DE (1) DE60018426T2 (es)
ES (1) ES2239019T3 (es)
IL (1) IL147716A0 (es)
MX (1) MXPA02000779A (es)
MY (1) MY125980A (es)
NZ (1) NZ516744A (es)
TW (1) TWI250164B (es)
WO (1) WO2001007472A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487465A4 (en) * 2002-02-11 2007-05-30 Arkion Life Sciences Llc CLEANED CYTOKIN-INHIBITING FACTOR
US20040005327A1 (en) * 2002-05-16 2004-01-08 Subramanian Iyer Immune T-cell stimulation
WO2006069779A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
US20080071067A1 (en) * 2006-09-20 2008-03-20 Avigenics, Inc. Methods of purifying proteins from egg white
US7852810B1 (en) * 2007-01-03 2010-12-14 Sprint Spectrum L.P. Dynamic adjustment of forward-link frame-error-rate (FFER) target
US7813323B1 (en) 2007-06-13 2010-10-12 Sprint Spectrum L.P. Dynamic adjustment of reverse-link frame-error-rate (RFER) target based on reverse-link RF conditions
US8107988B1 (en) 2008-07-25 2012-01-31 Sprint Spectrum L.P. Conducting power control based on reverse-link RF conditions
AU2009289484B2 (en) * 2008-09-05 2014-10-23 Cardiopolymers, Inc Apparatus and method for capsule formation in tissue
US8477686B1 (en) 2009-09-10 2013-07-02 Sprint Spectrum L.P. Automatic increase of target frame error rate for duration based on call drop timer
US8290532B1 (en) 2010-04-19 2012-10-16 Sprint Spectrum L.P. Selectively conducting reverse-link power control and call admission control
US8537700B1 (en) 2010-04-19 2013-09-17 Sprint Spectrum L.P. Identifying and selectively controlling reverse-noise contribution on a per-access-terminal basis
CN104288769B (zh) * 2014-09-17 2017-09-29 陕西建华生物制药有限公司 一种西药外用膏剂及其制备方法
JP5894695B1 (ja) * 2015-05-25 2016-03-30 ホーユー株式会社 ウズラの卵アレルギーの抗原
US10632158B2 (en) 2016-06-23 2020-04-28 IgY Nutrition Use of a hyperimmune egg product to prevent and treat dysbiosis
WO2018148734A1 (en) 2017-02-13 2018-08-16 The United States Of America, As Represented By The Secretary Of Agriculture Hyperimmunized egg product for treatment of necrotic enteritis in poultry

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119279D0 (en) * 1991-09-10 1991-10-23 Ici Plc Modification of lignin synthesis in plants
WO1998028419A2 (en) * 1996-12-20 1998-07-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulation of vesicular release

Also Published As

Publication number Publication date
ATE290017T1 (de) 2005-03-15
US6420337B1 (en) 2002-07-16
ES2239019T3 (es) 2005-09-16
MY125980A (en) 2006-09-29
IL147716A0 (en) 2002-08-14
NZ516744A (en) 2004-01-30
TWI250164B (en) 2006-03-01
DE60018426T2 (de) 2006-05-11
JP2003506019A (ja) 2003-02-18
EP1198475A4 (en) 2003-05-14
EP1198475B1 (en) 2005-03-02
CO5290297A1 (es) 2003-06-27
WO2001007472A1 (en) 2001-02-01
EP1198475A1 (en) 2002-04-24
JP4763193B2 (ja) 2011-08-31
AU6110600A (en) 2001-02-13
BR0013043A (pt) 2002-04-30
MXPA02000779A (es) 2003-10-15
AU778239B2 (en) 2004-11-25
US20030143190A1 (en) 2003-07-31
CA2379251A1 (en) 2001-02-01
CN1376163A (zh) 2002-10-23
DE60018426D1 (de) 2005-04-07

Similar Documents

Publication Publication Date Title
AR033340A1 (es) Factor activador de la citoquina altamente purificado y metodos de uso
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DE69130262T2 (de) Isolierte virale proteine als cytokinantagonisten
CL2012001063A1 (es) Anticuerpo humano que se une a interleuquina 18 humana (il-18h), metodo de preparacion, acidos nucleicos que lo dosifican, composicion que los contiene, uso en la preparacion de un medicamento para tratar patologias mediadas por il-18h. (divisional sol. 316-01).
AR038568A1 (es) Anticuerpos anti-a beta y su uso
FI972390A (fi) Sytokiini nimeltä Lerk-7
BR9808881A (pt) Compostos para imunoterapia de câncer de próstata e métodos para seu uso
EA199801031A1 (ru) Ингибиторы протеинфарнезилтрансферазы
AR001811A1 (es) Anticuerpos anti-icam-1 modificados y su uso en eltratamiento de inflamaciones
BR0114646A (pt) anticorpos anti-lt-beta-r humanizados
FI961251A (fi) Ihmisten metabotrooppiset glutamaattireseptorialatyypit(HMR4, HMR6, HMR7)ja niihin liittyvät DNA-yhdisteet
WO1996034107A3 (en) Antiviral proteins, dna coding sequences therefor, and uses thereof
AR021139A1 (es) Acidos nucleicos y polipeptidos de activadores de la transcripcion y metodos de uso de los mismos
FI965297A (fi) Uusi LERK-5:ksi nimetty sytokiini
ES2196026T3 (es) Uso de ndv en la fabricacion de un medicamento para tratar el cancer.
DK0746398T3 (da) Antistofrensning
NO326660B1 (no) Imidazolyl-cykliske acetal forbindelser, farmasøytiske sammensetninger inneholdende disse forbindelser og anvendelse av forbindelsene
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
DE69332861T2 (de) Neues protein aus urin, komponent b genannt
DE69731611D1 (de) Eine Zusammensetzung enthaltend eine Detergenz und einen ein Tumorsuppressorgen kodierenden, adenoviralen Vektor
DE69637844D1 (de) Neues tgf-beta-ahnliches cytokin
DE69317282D1 (de) Anti-Rezeptor Antikörper gegen den Vitamin B12/transcobalamin II Rezeptor
BR0312521A (pt) Métodos para a separação e a purificação de fibrinogênio e de pelo menos uma outra proteìna e para a co-purificação de fibrinogênio e de fator xiii, uso de cromatografia de afinidade com ìon de metal imobilizado, fibrinogênio, kit farmacêutico, e, formulações farmacêutica e de fibrinogênio liofilizado
ATE331728T1 (de) Proteinmarkierung mit radioaktivem phospor und gezielte radiotherapie
AR022150A1 (es) Acidos nucleicos derivados de monocitos y composiciones y metodos relacionados

Legal Events

Date Code Title Description
FA Abandonment or withdrawal